UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2005
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon | | 93-1099680 |
(State or other jurisdiction of incorporation
or organization) | | (I.R.S. Employer Identification No.) |
| | |
211 Somerville Road, Route 202 North,
Bedminster, NJ | | 07921 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (908) 470-2800
Former name or former address if changed since last report: no change
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
Item | | Description | |
| | | |
Item 5.02 | | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers | |
| | | |
Signatures | |
1
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On August 4, 2005, the Board of Directors of Bioject Medical Technologies Inc. elected Joseph Bohan as a Class II Director. Mr. Bohan was added to the Corporate Governance and Nominating Committee and the Ad-Hoc Financing Committee of the Board of Directors.
There are no arrangements or understandings between Mr. Bohan and any other persons pursuant to which Mr. Bohan was elected Director and there have not been any related party transactions in which the amount involved exceeded $60,000 with Mr. Bohan within the past year nor are any such transactions currently proposed.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August 8, 2005 | BIOJECT MEDICAL TECHNOLOGIES INC. |
| (Registrant) |
| |
| |
| /s/ JOHN GANDOLFO | |
| John Gandolfo |
| Chief Financial Officer and Vice President of Finance |
3
